دورية أكاديمية
Site-directed M2 proton channel inhibitors enable synergistic combination therapy for rimantadine-resistant pandemic influenza
| العنوان: | Site-directed M2 proton channel inhibitors enable synergistic combination therapy for rimantadine-resistant pandemic influenza |
|---|---|
| المؤلفون: | Scott, C, Kankanala, J, Foster, TL, Goldhill, DH, Bao, P, Simmons, K, Pingen, M, Bentham, M, Atkins, E, Loundras, E, Elderfield, R, Claridge, JK, Thompson, J, Stilwell, PR, Tathineni, R, McKimmie, CS, Targett-Adams, P, Schnell, JR, Cook, GP, Evans, S, Barclay, WS, Foster, R, Griffin, S |
| بيانات النشر: | Public Library of Science |
| سنة النشر: | 2020 |
| المجموعة: | White Rose Research Online (Universities of Leeds, Sheffield & York) |
| الوصف: | Pandemic influenza A virus (IAV) remains a significant threat to global health. Preparedness relies primarily upon a single class of neuraminidase (NA) targeted antivirals, against which resistance is steadily growing. The M2 proton channel is an alternative clinically proven antiviral target, yet a near-ubiquitous S31N polymorphism in M2 evokes resistance to licensed adamantane drugs. Hence, inhibitors capable of targeting N31 containing M2 (M2-N31) are highly desirable. Rational in silico design and in vitro screens delineated compounds favouring either lumenal or peripheral M2 binding, yielding effective M2-N31 inhibitors in both cases. Hits included adamantanes as well as novel compounds, with some showing low micromolar potency versus pandemic “swine” H1N1 influenza (Eng195) in culture. Interestingly, a published adamantane-based M2-N31 inhibitor rapidly selected a resistant V27A polymorphism (M2-A27/N31), whereas this was not the case for non-adamantane compounds. Nevertheless, combinations of adamantanes and novel compounds achieved synergistic antiviral effects, and the latter synergised with the neuraminidase inhibitor (NAi), Zanamivir. Thus, site-directed drug combinations show potential to rejuvenate M2 as an antiviral target whilst reducing the risk of drug resistance. |
| نوع الوثيقة: | article in journal/newspaper |
| وصف الملف: | text |
| اللغة: | English |
| العلاقة: | https://eprints.whiterose.ac.uk/164541/1/journal.ppat.1008716.pdfTest; Scott, C, Kankanala, J, Foster, TL et al. (20 more authors) (2020) Site-directed M2 proton channel inhibitors enable synergistic combination therapy for rimantadine-resistant pandemic influenza. PLOS Pathogens, 16 (8). e1008716. ISSN 1553-7366 |
| الإتاحة: | https://eprints.whiterose.ac.uk/164541Test/ https://eprints.whiterose.ac.uk/164541/1/journal.ppat.1008716.pdfTest |
| حقوق: | cc_by_4 |
| رقم الانضمام: | edsbas.31E0C762 |
| قاعدة البيانات: | BASE |
| الوصف غير متاح. |